PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-30.95%
Both yoy net incomes decline, with GNPX at -8.83%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-12.50%
Both reduce yoy D&A, with GNPX at -14.31%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Negative yoy SBC while GNPX is 300.02%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
710.07%
Slight usage while GNPX is negative at -1504.55%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
478.18%
A yoy AP increase while GNPX is negative at -229.53%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
8.45%
Some yoy usage while GNPX is negative at -92.99%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-100.00%
Negative yoy while GNPX is 431.55%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-8.11%
Both yoy CFO lines are negative, with GNPX at -9.40%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
100.00%
CapEx growth well above GNPX's 100.00%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower net investing outflow yoy vs. GNPX's 207.38%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
-50.00%
We cut debt repayment yoy while GNPX is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-32.24%
Both yoy lines negative, with GNPX at -99.69%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.